Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. The company is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone856-697-1441
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$65.86 million
Profitability
Miscellaneous
Employees189
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Teligent (NASDAQ:TLGT) Frequently Asked Questions
What is Teligent's stock symbol?
Teligent trades on the NASDAQ under the ticker symbol "TLGT."
How were Teligent's earnings last quarter?
Teligent Inc (NASDAQ:TLGT) posted its quarterly earnings data on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.01. The firm had revenue of $18.34 million for the quarter, compared to the consensus estimate of $17.58 million. Teligent had a negative return on equity of 102.17% and a negative net margin of 46.67%. View Teligent's Earnings History.
When is Teligent's next earnings date?
What price target have analysts set for TLGT?
2 brokerages have issued 12 month target prices for Teligent's stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Teligent's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 316.7% from the stock's current price. View Analyst Price Targets for Teligent.
What is the consensus analysts' recommendation for Teligent?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teligent in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teligent.
Has Teligent been receiving favorable news coverage?
News headlines about TLGT stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Teligent earned a news impact score of -2.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Teligent.
Are investors shorting Teligent?
Teligent saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 8,070,000 shares, a drop of 6.4% from the August 30th total of 8,620,000 shares. Based on an average trading volume of 374,300 shares, the days-to-cover ratio is presently 21.6 days. Currently, 18.6% of the shares of the stock are short sold. View Teligent's Current Options Chain.
Who are some of Teligent's key competitors?
Some companies that are related to Teligent include TAIWAN LIPOSOME/S (TLC), XOMA (XOMA), Five Prime Therapeutics (FPRX), Tyme Technologies (TYME), Cerecor (CERC), Sol Gel Technologies (SLGL), Arcturus Therapeutics (ARCT), Axovant Sciences (AXON), Concert Pharmaceuticals (CNCE), Aldeyra Therapeutics (ALDX), Hookipa Pharma (HOOK), Calithera Biosciences (CALA), Ocular Therapeutix (OCUL), Northwest Biotherapeutics (NWBO) and Axovant Gene Therapies (AXGT).
What other stocks do shareholders of Teligent own?
Who are Teligent's key executives?
Teligent's management team includes the folowing people:
- Mr. Jason Grenfell-Gardner M.B.A., M.B.A, Pres, CEO & Director (Age 44)
- Mr. Stephen Richardson, Chief Scientific Officer (Age 53)
- Mr. Martin Wilson, Gen. Counsel (Age 42)
- Mr. Damian Finio, Corp. Sec. & CFO (Age 49)
- Ms. Nadya Lawrence, Sr. VP of Technical Services (Age 50)
How do I buy shares of Teligent?
Shares of TLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Teligent's stock price today?
One share of TLGT stock can currently be purchased for approximately $0.72.
How big of a company is Teligent?
Teligent has a market capitalization of $38.77 million and generates $65.86 million in revenue each year. The company earns $-36,260,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Teligent employs 189 workers across the globe.View Additional Information About Teligent.
What is Teligent's official website?
How can I contact Teligent?
Teligent's mailing address is 105 LINCOLN AVENUE, BUENA NJ, 08310. The company can be reached via phone at 856-697-1441 or via email at [email protected]
MarketBeat Community Rating for Teligent (NASDAQ TLGT)
MarketBeat's community ratings are surveys of what our community members think about Teligent and other stocks. Vote "Outperform" if you believe TLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
